Table 1 Baseline characteristics of patients
Characteristics, n (%) | Selumetinib + docetaxel (N = 35) | Selumetinib + dacarbazine (N = 25) |
|---|---|---|
Age, years; mean (SD) | 58.9 (9.5) | 57.1 (11.5) |
Male | 21 (60.0) | 15 (60.0) |
Female | 14 (40.0) | 10 (40.0) |
Race | ||
White | 33 (94.3) | 25 (100.0) |
Black/African American | 2 (5.7) | 0 |
WHO performance status | ||
0 | 14 (40.0) | 12 (48.0) |
1 | 21 (60.0) | 13 (52.0) |
Primary tumor site | ||
Skin/soft tissue | 11 (31.4) | 17 (68.0) |
Lung | 8 (22.9) | 3 (12.0) |
Breast | 3 (8.6) | 0 |
Colorectal | 2 (5.7) | 0 |
Esophagus | 2 (5.7) | 0 |
Ovary | 2 (5.7) | 0 |
Head and neck | 1 (2.9) | 1 (4.0) |
Uveal | 1 (2.9) | 1 (4.0) |
Othera | 5 (14.3) | 3 (12.0) |
Mean prior systemic treatments | 3.1 | 2.0 |
Prior therapy, n (%) | ||
Chemotherapy | 30 (85.7) | 18 (72.0) |
Platinum compounds | 24 (68.6) | 9 (36.0) |
Taxanes | 18 (51.4) | 8 (32.0) |
Pyrimidine analogues | 6 (17.1) | 1 (4.0) |
Anthracyclines | 5 (14.3) | 3 (12.0) |
Radiotherapy | 18 (51.4) | 13 (52.0) |
Other systemic anticancer therapyb | 8 (22.9) | 8 (32.0) |
Immuno/hormonal therapy | 6 (17.1) | 0 |
Hormonal therapy | 3 (8.6) | 0 |
Immunotherapy | 2 (5.7) | 10 (40.0) |
Prior lines of chemotherapy, n (%) | ||
0 or 1 | 17 (48.6) | 21 (84.0) |
2 or 3 | 10 (28.6) | 2 (8.0) |
4+ | 8 (22.9) | 2 (8.0) |